Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis
Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin
Department of Hematology, Wuxi People′s Hospital Affiliated to Nanjing Medical University, Wuxi 214000, China
Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin. Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis[J]. Journal of International Oncology, 2018, 45(6): 347-351.
[1] Song MK, Chung JS, Seol YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large Bcell lymphoma with RCHOP therapy[J]. Ann Oncol, 2010, 21(1): 140-144. DOI: 10.1093/annonc/mdp505.
[2] Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes: independent prognostic value of the absolute lymphocyte count[J]. Am J Hematol, 2010, 85(3): 160-163. DOI: 10.1002/ajh.21618.
[3] Mao J, Cheng F, Chen H, et al. Shortcourse bortezomibbased retreatment for patients with multiple myeloma who had received bortezomibthalidomidedexamethasone (VTD) as an initial therapy: a singlecenter case series[J]. Exp Ther Med, 2014, 7(4): 977-981. DOI: 10.3892/etm.2014.1496.
[4] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第三版. 北京: 科学出版社, 2007: 232-235.
[5] Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study[J]. Br J Haematol, 2008, 141(6): 792-798. DOI: 10.1111/j.1365-2141.2008.07123.x.
[6] Song MK, Chung JS, Joo YD, et al. Clinical value of absolute lymphocyte counts before bortezomibdexamethasone therapy in relapsed multiple myeloma patients[J]. Acta Haematol, 2010, 124(1): 34-39. DOI: 10.1159/000313654.
[7] 杨瑞芳, 赵志红, 张鹏. 淋巴细胞绝对计数与多发性骨髓预后的相关性分析[J]. 中国肿瘤临床, 2013, 40(20): 1224-1226. DOI: 10.3969/j.issn.1000-8179.20121876.
[8] Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party[J]. J Clin Oncol, 2005, 23(36): 9219-9226. DOI: 10.1200/JCO.2005.03.2086.
[9] Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma[J]. Br J Haematol, 2007, 138(5): 563-579. DOI: 10.1111/j.1365-2141.2007.06705.x.
[10] Pellom ST, Dudimah DF, Thounaojam MC, et al. Modulatory effects of bortezomib on host immune cell functions[J]. Immunotherapy, 2015, 7(9): 1011-1022. DOI: 10.2217/imt.15.66.